Cumberland Pharmaceuticals Inc（CPIX）股票分析CPIXCumberland Pharmaceuticals Inc

Cumberland Pharmaceuticals Inc. is an innovation-focused biopharmaceutical company developing new product candidates for rare diseases and other serious conditions. Its product candidates include Dyscorban (ifetroban), Vasculan (ifetroban) and Fibroban. Dyscorban (ifetroban) oral capsule is being developed for the treatment of the cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Vasculan (ifetroban) oral capsule has been developed for the treatment of systemic sclerosis (SSc), also known as scleroderma. It is a rare autoimmune disorder that results in a thickening of the skin and internal organs. Fibroban oral capsule is developed for the treatment of idiopathic pulmonary fibrosis (IPF). Its commercial products include Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ. Acetadote (acetylcysteine) injection has been developed for the treatment of acetaminophen poisoning. Caldolor (ibuprofen) injection is developed for the treatment of pain and fever. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Cumberland Pharmaceuticals Inc (CPIX) appears to be a good buy right now due to its current price of $8.46, which is near its recent 52-week high of $8.45, supported by a strong 5-day price change of +10.59% and a year-to-date change of +112.56%. The company has also announced a special dividend of $1.50 per share, reflecting a commitment to shareholder returns. However, the main risk is its negative net income of -3.1 million in Q2 2026, which indicates ongoing financial challenges.

1 analysts cover CPIX: 0 rate it Buy, 1 Hold and 0 Sell.